Retatrutide vs Mazdutide
Head-to-head comparison of Retatrutide and Mazdutide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Retatrutide | Mazdutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Dual GLP-1/Glucagon Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). | Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor. |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase I–II Clinical Trials |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Approved in China (June 2024) for chronic weight management. Phase III in China for T2D. Not yet approved outside China. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common: GI side effects including nausea, vomiting, diarrhea (similar to GLP-1 agonist class); GI adverse events are dose-dependent and generally transient |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 3–9 mg SC once weekly (approved in China at 9 mg for obesity) |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | ~4233.7 g/mol |
| Half-Life | ~6 days (allows once-weekly dosing) | Suitable for once-weekly dosing (exact value not fully published) |
Overview
Retatrutide and Mazdutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Mazdutide — Mechanism & Evidence
Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW 4,563.06 g/mol). It is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, aiming to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. China's NMPA approved mazdutide in June 2025 for chronic weight management and in September 2025 for glycaemic control in type 2 diabetes, making it the first dual GLP-1/glucagon agonist approved anywhere in the world.
Key claims: Significant weight loss in Chinese adults with obesity; Effective glycemic control; Reduces hepatic fat content.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Mazdutide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Mazdutide: Common: GI side effects including nausea, vomiting, diarrhea (similar to GLP-1 agonist class) GI adverse events are dose-dependent and generally transient Heart rate increase observed, consistent with GLP-1 agonist class effect
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
BPC-157 5mg
5mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe